1. Home
  2. VOXR vs CHRS Comparison

VOXR vs CHRS Comparison

Compare VOXR & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vox Royalty Corp.

VOXR

Vox Royalty Corp.

HOLD

Current Price

$5.40

Market Cap

362.5M

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.59

Market Cap

291.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VOXR
CHRS
Founded
2014
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
362.5M
291.5M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
VOXR
CHRS
Price
$5.40
$1.59
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
508.4K
1.3M
Earning Date
02-20-2026
03-09-2026
Dividend Yield
0.97%
N/A
EPS Growth
N/A
472.00
EPS
N/A
1.43
Revenue
N/A
N/A
Revenue This Year
$39.87
$88.67
Revenue Next Year
$90.76
$28.64
P/E Ratio
N/A
$1.11
Revenue Growth
N/A
N/A
52 Week Low
$2.59
$0.72
52 Week High
$6.59
$2.62

Technical Indicators

Market Signals
Indicator
VOXR
CHRS
Relative Strength Index (RSI) 42.90 40.19
Support Level $4.76 $1.55
Resistance Level $5.48 $1.75
Average True Range (ATR) 0.37 0.11
MACD -0.09 -0.01
Stochastic Oscillator 3.23 2.33

Price Performance

Historical Comparison
VOXR
CHRS

About VOXR Vox Royalty Corp.

Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: